Home
10th Annual Superbugs & Superdrugs Conference
9 April - 10 April 2008
10th Annual Superbugs & Superdrugs Conference
The global anti-infective market is currently valued at US$66.5 billion with antibacterial agents accounting for over 50% of sales. The antibacterial market is set to grow to over US$45.0 billion by 2012, driven by the uptake of newer antibacterial agents such as glycopeptides and carbapenems which demonstrate resistance to methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE) as well as other emerging strains.

Pharmaceutical companies continue to develop a new generation of antibacterial agents such as cephalosporins, macrolides and quinolones to overcome the major issue of drug resistance but this is not without the struggle and threat of bacterial resistance.

By attending SAE Media Group’s 10th Annual Superbugs & Superdrugs; A focus on antibacterials conference, you will be able to:

DISCOVER the main antibacterial targets that are worth investing in.
LEARN state-of-the-art therapeutic mAbs for bacterial infections.
UNDERSTAND pioneering antisense strategies for bacteria.
DIVE into the R&D pipeline and inspect the novel advances in drug development.
FAMILIARISE yourself with up-to-date regulatory aspects.
UPDATES on Phage therapy, quorum sensing, and diagnostics.
ASCERTAIN pioneering developments in both gram-positive and gram-negative bacteria.
Do not miss this opportunity to find out the incentives for development and learn of the advances in the pipeline for antibacterials.
Hear international case studies and expert opinions from leaders in the field, including:
  • Dr Kenneth Tack, Executive Director, Targanta
  • Dr Neil S Ryder, Executive Director, Infectious Diseases, Novartis
  • Dr Paul Miller, Executive Director, Anti-Bacterials, Pfizer
  • Dr Brian Noonan, Director of Molecular Bioscience, AstraZeneca
  • Dr Jeff Hermes, Senior Director Microbil Biochemistry, Merck
  • Dr Monique Twynholm, Director, Anti-Infectives, GlaxoSAE Media GroupthKline
  • Dr E David G McIntosh, Medical Director Infectious Diseases, Wyeth
  • Dr Lloyd Czaplewski, Director of Research, Prolysis
  • Prof. Malcolm G. P. Page, Head of Biology, Basilea
  • Dr William Weiss, Director, Drug Evaluation, Cumbre Pharmaceuticals
  • Dr Beatrice Allain, Director, Therapeutic Division, Biophage Pharma
  • Dr Ly Tam Phan, Senior Director Medicinal Chemistry, Enanta Pharmaceuticals
  • Dr Jeff Alder, Vice Presedent, Drug Discovery and Evaluation, Cubist Pharmaceuticals
  • Dr Nafsika Georgopapadakou, Vice President of Research, Novabay Pharmaceuticals

  • Dr Albert Collinson, Chief Business Officer, Rib - X - Pharmaceuticals

  • Dr Nora Kaarela, Chief Executive Officer, IPSAT Therapies

  • Dr Hans-Henrik Kristensen, Senior manager, Novozymes A / S

  • Dr Thomas Henkel, CEO, Intermed Discovery GmBh

Who should attend Superbugs & Superdrugs?
You should attend this conference if you are an Executive, Director, Chemist or Scientist working in the pharmaceutical or biotech industries within:
  • Microbiology
  • Immunology
  • Infectious Diseases
  • Medicinal Chemistry

Conference agenda

clock

13:30

Registration & Coffee

clock

14:00

Welcome and Introduction

clock

14:10

Biophage Pharma profile and business focus

  • Phage Therapy
  • Biosensors
  • Immunology / Immunotoxicology
  • Beatrice Allain

    Beatrice Allain, Director, Biophage Pharma Inc

    Gilbert Pichette

    Gilbert Pichette, Director, Biophage Pharma Inc

    clock

    14:40

    Phage Therapy: Taking advantage of viruses to fight bacteria

  • Early work in Eastern countries
  • Recent advances in phage therapy
  • Safety issues: groundbreaking announcement from FDA
  • Beatrice Allain

    Beatrice Allain, Director, Biophage Pharma Inc

    Gilbert Pichette

    Gilbert Pichette, Director, Biophage Pharma Inc

    clock

    15:00

    Phage product development: How to turn a phage into a marketable product

  • Technologies and methodologies
  • Large-scale phage production
  • Ready to market product
  • Beatrice Allain

    Beatrice Allain, Director, Biophage Pharma Inc

    Gilbert Pichette

    Gilbert Pichette, Director, Biophage Pharma Inc

    clock

    15:30

    Afternoon Tea

    clock

    16:00

    Biophage Pharma environmental-friendly phage program to fight bacterial contamination

  • Bacterial contamination issues
  •  Phages for food safety
  •  Phages as environmentally-safe disinfectant
  •  Phages therapy: when antibiotics are not working anymore
  •  Phage Theranostic: a personalized medicine combining diagnostic and phage therapy
  • Beatrice Allain

    Beatrice Allain, Director, Biophage Pharma Inc

    Gilbert Pichette

    Gilbert Pichette, Director, Biophage Pharma Inc

    clock

    16:40

    Discussion and questions – review of the session

    Beatrice Allain

    Beatrice Allain, Director, Biophage Pharma Inc

    Gilbert Pichette

    Gilbert Pichette, Director, Biophage Pharma Inc

    clock

    17:30

    End of Session

    clock

    8:30

    Registration & Coffee

    clock

    9:00

    Chairman's Opening Remarks

    Malcolm Page

    Malcolm Page, Head, Biology, Basilea Pharmaceutica

    clock

    9:10

    CASE STUDY OF DRUG DEVELOPMENT – ORITAVANCIN

    Kenneth Tack

    Kenneth Tack, Senior Director, Targanta Therapeutics

  • History of the compound
  • Chemistry
  • In-vitro activity
  • Animal Studies
  • Clinical Trials
  • clock

    9:50

    OVERCOMING RESISTANCE BY DESIGN

    Albert Collinson

    Albert Collinson, Chief Business Officer, Rib - X - Pharmaceuticals Inc

  • Attacking multi-drug resistant bacteria via the ribosome
  • Discovery and development of new highly potent antibiotics
  • Achieving success in the clinic against resistant bacteria
  • clock

    10:30

    Morning Coffee

    clock

    10:50

    PHAGE THERANOSTIC

    Beatrice Allain

    Beatrice Allain, Director, Biophage Pharma Inc

  • Presentation of phage therapy
  • Recent advances in phage therapy
  • Diagnostic as pre-requisite to efficient phage therapy
  • Advance in rapid diagnostic
  • Phage-Theranostic
  • clock

    11:30

    ALTERNATIVE SOLUTIONS TO PREVENTING HOSPITAL INFECTIONS AND ANTIBIOTIC RESISTANCE

    Nora Kaarela

    Nora Kaarela, Chief Executive Officer, IPSAT Therapies

  • The protective role of the intestinal microflora
  • Secondary infections and antibiotic resistance - unwanted "companions" of antibiotic treatment
  • Novel approach to preserve intestinal microflora during antibiotic treatment
  • Latest results from Phase IIB studies
  • clock

    12:10

    BACTERIAL DRUG RESISTANCE

    Jeffrey Alder

    Jeffrey Alder, Global Clinical Microbiology, Bayer Healthcare

  • Different and conflicting criteria for drug resistance
  • Reporting bias in drug resistance: over or under reported?
  • Drug Resistance and Clinical failure: cause and effect?
  • Impact of Drug Resistance criteria on Drug Discovery and Development
  • clock

    12:50

    Networking Lunch

    clock

    13:50

    NEW APPROACHES TO OLD TARGETS

    David  McIntosh

    David McIntosh, Medical Director, Infectious Diseases, Wyeth

  • Tetracyclines act by inhibiting bacterial protein synthesis
  • The efficacy of tetracyclines has been compromised by the development of resistance
  • Efflux is a powerful form of resistance compromising the tetracyclines
  • Tigecycline is a glycylcycline, developed to overcome mechanisms of tetracycline resistance
  • clock

    14:30

    THE SEARCH FOR NOVEL ANTIBACTERIAL AGENTS

    Brian Noonan

    Brian Noonan, Director of Molecular Bioscience, Infection Discovery, AstraZeneca

  • The challenge of antibacterial lead generation
  • Approaches to identifying novel hit compounds
  • Turning hits into leads
  • clock

    15:10

    Afternoon Tea

    clock

    15:30

    A BROAD SPECTRUM BETA LACTAMASE INHIBITOR TO ADDRESS GRAM NEGATIVE RESISTANCE

    Christine Miossec

    Christine Miossec, Biology, NOVEXEL

  • Increasing prevalence in ESBLs, class A carbapenemases, and Gram negative pathogens producing multiple ß-lactamases
  • No new classes of antibiotics in development to address Gram negative resistance
  • ß-lactam plus ß-lactamase inhibitor proven strategy; available agents class A only
  • NXL104 has a promising profile
  • Addressing clinical and regulatory challenges in development of ß-lactam, ß-lactamase inhibitor combinations
  • clock

    16:10

    MULTIDRUG-RESISTANT GRAM-NEGATIVE BACTERIA

    Malcolm Page

    Malcolm Page, Head, Biology, Basilea Pharmaceutica

  • Problem pathogens (drug-resistance in E. coli, K. Pneumoniae, P. aeruginosa and A. baumannii)
  • Resistance mechanisms in E. coli and K. pneumoniae
  • Resistance mechanisms in P. aeruginosa and A. baumannii
  • Activity of new agents, and compounds in late-stage clincal development, against MDR
  • Activity of experimental compounds in early stage clinical development
  • clock

    16:50

    TWO NEW ANTIBACTERIALS WITH NOVEL MECHANISMS OF ACTION

    Lloyd Czaplewski

    Lloyd Czaplewski, Director, Research, Prolysis

  • Use of fragment-based drug design & whole cell screening to create new antibacterials
  • Characterisation of FtsZ inhibitors as targeted anti-staphylococcal & anti-clostridial agents
  • Potent GyrB inhibitors active against resistant Gram-positives and community-acquired RTI’s
  • clock

    17:30

    Chairman’s Closing Remarks and Close of Day One

    clock

    8:30

    Registration & Coffee

    clock

    9:00

    Chairman's Opening Remarks

    Neil Ryder

    Neil Ryder, Executive Director, Novartis Institutes for Biomedical Research Inc.

    clock

    9:10

    ANTIBACTERIAL DRUG RESISTANCE

    Neil Ryder

    Neil Ryder, Executive Director, Novartis Institutes for Biomedical Research Inc.

  • Basic mechanisms of resistance
  • Common features of bacteria
  • Impact of resistance in selection of drug targets, with some recent examples
  • Advances in antibacterial drug discovery
  • How this can be compared to antifungal drug discovery
  • The road ahead
  • clock

    9:50

    CLINICAL DEVELOPMENT OF ANTIBIOTICS IN THE 21ST CENTURY

    Monique Twynholm

    Monique Twynholm, Associate Director, Anti-infectives, GlaxoSmithKline

  • Unmet medical need
  • Current hurdles in Antibiotic clinical development
  • Innovative study designs
  • Placebo controlled or superiority studies
  • Patient reported outcome measures in clinical trials
  • clock

    10:30

    Morning Coffee

    clock

    10:50

    CHEMICAL POST-EVOLUTION OF ANTIBACTERIAL NATURAL PRODUCTS

    Paul Miller

    Paul Miller, Executive Director of Antibacterials , Pfizer

  • Examining lead structure variants
  • Structural and Physiochemical requirements for antibacterial activity
  • What is the track record for the success of natural products?
  • clock

    11:30

    PLECTASIN DERIVATIVE NZ2114

    Hans-Henrik Kristensen

    Hans-Henrik Kristensen, Senior manager, Novozymes A / S

  • Potent in vitro activity against gram-positive bacteria including MRSA and VRSA
  • Therapeutic activity in animal models of infection
  • Novel mechanism of action compared to clinically used antibiotics
  • Pre-clinical tox-safety data
  • clock

    12:10

    NATURAL PRODUCT (NP) BASED ANTIBACTERIALS

    Thomas Henkel

    Thomas Henkel, Chief Executive Officer, Intermed Discovery GmBh

  • Some successes from the past and actual examples
  • What are the obstacles?
  • General potential of Natural Products - a prediction
  • Perspectives for the future
  • clock

    12:50

    Networking Lunch

    clock

    13:50

    STRATEGIES TO BROADEN CARBAPENEM ACTIVITY VS. RESISTANT PATHOGENS

    Jeff Hermes

    Jeff Hermes, Senior Director, Merck

  • Carbapenem antibiotics have been a mainstay of empiric therapy for two decades
  • However, carbapenem resistance in key Gram-negative pathogens has become problematic in nosocomial infections (e.g. P. aeruginosa and K. pneumoniae)
  • Few therapeutic options exist to cover these multi-drug resistant Gram-negative pathogens
  • In addition, MRSA prevalence is significant and marketed carbapenems never afforded coverage of this increasingly important Gram-positive organism
  • Can adjunct agents rescue the widely utilized carbapenem class of antibiotics?
  • clock

    14:30

    GASTROINTESTINAL DISEASES

    William Weiss

    William Weiss, Director, Drug Evaluation, Cumbre Pharmaceuticals

  • Background of disease states
  • Prevalence / epidemiology / resistance
  • Target product profiles
  • Therapy: standard of care
  • New and emerging agents
  • clock

    15:10

    Afternoon Tea

    clock

    15:30

    TACKLING B-LACTAMASE-ASSOCIATED RESISTANCE MECHANISMS

    Nafsika Georgopapadakou

    Nafsika Georgopapadakou, Vice President Research, NovaBay Pharmaceuticals

  • The ABCs of B-lactamases
  • Approaches to reduce resistance:  attacking v. co-opting B-lactamases
  • What properties should an inhibitor have?  A pro-drug?
  • Emerging micro-organisms and the hurdles they pose
  • Multidrug resistance - its impact on B-lactamase-associated resistance
  • Future trends and therapeutic options
  • clock

    16:10

    NEW BICYCLOLIDES ACTIVE AGAINST MRSA AND VRE

    Ly Phan

    Ly Phan, Director, Medicinal Chemistry, Enanta Pharmaceuticals

  • Recent advances in macrolide research against  MRSA and VRE
  • clock

    16:50

    Chairman’s Closing Remarks and Close of Conference

    Crowne Plaza Hotel - The City

    19 New Bridge Street
    London EC4V 6DB
    United Kingdom

    Crowne Plaza Hotel - The City

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content

    Title


    Description

    Download

    Title


    Description

    Download

    Title


    Description


    Download

    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SAE Media Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@saemediagroup.com

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    Group Booking

    Please complete the below form and a member of SAE Media Group’s booking team will be in contact within 24 hours

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Contact SAE Media Group

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SAE Media Group , Ground Floor, India House, 45 Curlew Street, London, SE1 2ND, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smgconferences.com Email: events@saemediagroup.com
    Registered in England - SMi Group Ltd trading as SAE Media Group


    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.

    Thank you for visiting our event

    If you would like to receive further information about our events, please fill out the information below.

    By ticking above you are consenting to receive information by email from SAE Media Group.
    Full details of our privacy policy can be found here https://www.smgconferences.com/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data.privacy@smgconferences.com.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smgconferences.com/opt-out

    Fill in your details to download the brochure

    By submitting this form you agree to our privacy policy and consent to receiving communications, you may opt out at any time.